ERCC1 and non-small cell lung carcinoma: The current study describes the predictive role of ERCC1 as determined by the 8F1 monoclonal antibody and AQUA technology in patients with stage IV NSCLC using a novel analytical methodology specifically developed for the assessment of biomarkers with continuous values (ABMS).